Diarrhea News and Research

Latest Diarrhea News and Research

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC).

23 Sep 2009

Survey: 77% of Latino women avoid milk to manage lactose intolerance

A new Lactose Intolerance in Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that 77 percent of Latinas reduce the amount of milk or dairy in their diet as a way to manage their lactose intolerance. Yet, 63 percent of Latinas who have lactose intolerance worry the condition keeps them from consuming important nutrients, such as calcium and vitamins A and D. Despite their concerns, only 14 percent have talked to a health care professional about lactose intolerance.

22 Sep 2009

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

22 Sep 2009

Survey: 78% of African American women avoid milk to manage lactose intolerance

A new Lactose Intolerance in Multicultural Communities Survey sponsored by the LACTAID(R) Brand found that 78 percent of African American women reduce the amount of milk or dairy in their diet as a way to manage their lactose intolerance. Yet, 48 percent of African American women who have lactose intolerance worry the condition keeps them from consuming important nutrients, such as calcium and vitamins A and D. Despite their concerns, only 16 percent have talked to a health care professional about lactose intolerance.

22 Sep 2009

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supportive care.

21 Sep 2009

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

King Pharmaceuticals(R), Inc. (NYSE: KG) today announced a true milestone as it marks the first commercial availability for EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

21 Sep 2009

H1N1 infected people continue to shed live virus days after the symptoms

ABC News and other outlets are reporting that two studies released on Tuesday suggest that people infected with the H1N1 virus continue to shed virus after the point where current recommendations say they can resume their normal activities.

19 Sep 2009

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

Notice of Allowance issued by PTO for OSI's EGFR drug

OSI Pharmaceuticals, Inc. announced today that the U.S. Patent & Trademark Office has issued a “Notice of Allowance” in OSI’s reissue application for U.S. Patent No.5,747,498 (the ‘498) composition of matter patent for Tarceva® (erlotinib). The reissued patent will replace the original ‘498 patent and have the same November 2018 expiration date.

18 Sep 2009

FDA approves Valturna tablets for treating high blood pressure

The US Food and Drug Administration (FDA) has approved Valturna((R)) (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

18 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

News outlets examine West Africa floods

The torrential rains that began in June in West Africa and subsequent floods have forced an estimated 150,000 people from their homes and claimed the lives of 160, VOA News reports. The worst affected countries include Senegal, Burkina Faso, Ghana, Niger and Sierra Leone (Schlein, 9/13).

17 Sep 2009

Also in Global Health news: Tanzania's health care; polio, diarrhea in India; ITNs in Nigeria; health in Sudan

Rotary International recently started working with the Indian government to fight diarrhea, which can make polio immunizations ineffective, IANS/Thaindian News reports. Deepak Kapur, chairman of the India National PolioPlus Society of Rotary International, said the plan is to educate people about the use of use of zinc tablets and oral rehydration therapy to prevent diarrhea, which kills almost 500,000 children per year in the country (Khan, 9/16).

17 Sep 2009

Pros and cons of HIV treatments in developing countries

Palumbo is co-leading a clinical study of anti-HIV medicines in Africa and India for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT). The randomized trial found that a cohort of 82 HIV-infected children ages 6 to 35 months responded better to treatment with the protease-inhibiting drug lopinavir (LPV/r) than did a cohort of 82 children in the same age group who received the anti-retroviral drug nevirapine (NVP).

16 Sep 2009

Patients with celiac disease face increased risk of mortality

New research indicates that patients with lesser degrees of celiac disease-related symptoms, such as intestinal inflammation or latent celiac disease, have a modestly increased risk of death, according to a study in the September 16 issue of JAMA.

16 Sep 2009

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

16 Sep 2009

Also in Global Health News: PNG, Nepal outbreaks; Taliban Oks polio vaccination; Technology helps in developing countries; Satellite images for malaria control

VOA News examines the ongoing struggle for Papua New Guinea's health system to treat thousands of people infected by the "simultaneous outbreaks of influenza, dysentery and cholera that have killed about 120 people." The article includes information about the difficulties heath officials are having in assessing the various outbreaks and concerns of medical workers that conditions may soon worsen (Mercer, 9/14).

16 Sep 2009

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing.

15 Sep 2009

Diarrhea News and Research

Latest Diarrhea News and Research

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Survey: 77% of Latino women avoid milk to manage lactose intolerance

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Survey: 78% of African American women avoid milk to manage lactose intolerance

Study reveals that patients with NSCLC who received maintenance therapy with ALIMTA showed survival benefit

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

H1N1 infected people continue to shed live virus days after the symptoms

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Millennium's sNDA for VELCADE granted priority review by the FDA

Notice of Allowance issued by PTO for OSI's EGFR drug

FDA approves Valturna tablets for treating high blood pressure

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

News outlets examine West Africa floods

Also in Global Health news: Tanzania's health care; polio, diarrhea in India; ITNs in Nigeria; health in Sudan

Pros and cons of HIV treatments in developing countries

Patients with celiac disease face increased risk of mortality

Optimer's North American phase 3 Fidaxomicin study results presented at the 49th ICAAC

Also in Global Health News: PNG, Nepal outbreaks; Taliban Oks polio vaccination; Technology helps in developing countries; Satellite images for malaria control

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in